Breaking Finance News

Sangamo BioSci (NASDAQ:SGMO) has been downgraded from Overweight to Neutral in a statement by Piper Jaffray earlier today.

Boasting a price of $3.90, Sangamo BioSci (NASDAQ:SGMO) traded -9.62% lower on the day. With the last stock price close down -37.09% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Sangamo BioSci has recorded a 50-day average of $4.51 and a two hundred day average of $5.60. Volume of trade was down over the average, with 800,820 shares of SGMO changing hands under the typical 932,146

Piper Jaffray has downgraded Sangamo BioSci (NASDAQ:SGMO) from Overweight to Neutral in a report released on Wednesday October 19, 2016.

See Chart Below

Sangamo BioSci (NASDAQ:SGMO)

Sangamo BioSci has a with a one year low of $3.50 and a one year high of $9.91 Sangamo BioSci’s market capitalization is presently $0.

General Company Details For Sangamo BioSci (NASDAQ:SGMO)

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics. Its ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. It has preclinical programs in hemophilia A and Lysergic acid diethylamide and research stage programs in monogenic diseases, including certain central nervous system disorders and cancer immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.